האיחוד האירופי - ליטאית - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumabas - išsėtinė sklerozė - selektyvūs imunosupresantai - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ir 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

האיחוד האירופי - ליטאית - EMA (European Medicines Agency)

sanofi-aventis - rimonabantas - nutukimas - antikoaguliantų preparatai, išskyrus dietos produktai - kaip papildoma priemonė kartu su dieta ir fiziniais pratimais gydyti nutukusiems pacientams (kmi yra 30 kg/m2), arba turi antsvorio pacientams (kmi 27 kg/m2) ir su ja susijusios rizikos veiksnys (- ai), tokių kaip 2 tipo diabetas arba dyslipidaemia (žr. skyrių 5.

האיחוד האירופי - ליטאית - EMA (European Medicines Agency)

biogen netherlands b.v. - nusinersen sodium - raumenų atrofija, nugaros smegenys - kiti nervų sistemos vaistai - "spinraza" skiriamas 5q raumenų raumens atrofijos gydymui.

ליטא - ליטאית - SMCA (Valstybinė vaistų kontrolės tarnyba)

pharmaand gmbh - klomipraminas - dengtos tabletės - 25 mg - clomipramine

ליטא - ליטאית - SMCA (Valstybinė vaistų kontrolės tarnyba)

merck sharp & dohme, uab - ezetimibas - tabletės - 10 mg - ezetimibe

ליטא - ליטאית - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva pharma b.v. - medazepamas - tabletės - 10 mg - medazepam

ליטא - ליטאית - SMCA (Valstybinė vaistų kontrolės tarnyba)

merck sharp & dohme, uab - imipenemas/cilastatinas - milteliai infuziniam tirpalui - 500 mg/500 mg - imipenem and cilastatin

האיחוד האירופי - ליטאית - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinoma, plazminė ląstelė - antinavikiniai vaistai - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

האיחוד האירופי - ליטאית - EMA (European Medicines Agency)

viiv healthcare b.v. - fostemsavir trometamol - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - rukobia, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant hiv-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

האיחוד האירופי - ליטאית - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumabas - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologai - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).